Marco Cefali
Overview
Explore the profile of Marco Cefali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pesola G, Epistolio S, Cefali M, Trevisi E, De Dosso S, Frattini M
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682112
The management of metastatic colorectal cancer in patients harboring RAS mutations primarily involves chemotherapy, often combined with bevacizumab, as a standard first-line treatment. However, emerging evidence suggests that tumors in...
2.
Ganz-Blaettler U, Liptrott S, Tolotti A, Cefali M, Aeschlimann C, Vilei S, et al.
Cancer Treat Rev
. 2024 Sep;
130:102822.
PMID: 39276429
The aim of this review is to provide an overview of the status of patient/public involvement (PPI) in oncology research, including definitions, regulatory aspects, ongoing clinical activities in different countries,...
3.
Erhart C, Cefali M, Mangan D, Kasenda B, Wannesson L
Swiss Med Wkly
. 2024 Aug;
154():3695.
PMID: 39137343
Aim: This study aims to evaluate the prognostic role of the KRAS G12C mutation in patients with advanced non-small cell lung cancer and PD-L1 expression ≥50% who are treated with...
4.
Roesel R, Deantonio L, Bernardi L, Garo M, Majno-Hurst P, Vannelli A, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760596
Background: Despite advances in treatment, the prognosis of resectable pancreatic adenocarcinoma remains poor. Neoadjuvant therapy (NAT) has gained great interest in hopes of improving survival. However, the results of available...
5.
Cefali M, Scala I, Pavone G, Helbling D, Hussung S, Fritsch R, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686674
Background: Malnutrition, loss of weight and of skeletal muscle mass are frequent in pancreatic cancer patients, a majority of which will undergo chemotherapy over the course of their disease. Available...
6.
Rizzo S, Scala I, Robayo A, Cefali M, De Dosso S, Cappio S, et al.
Front Oncol
. 2022 Oct;
12:974116.
PMID: 36249069
Objectives: The objective of this systematic review was to assess associations between quantitative body composition measures extracted from imaging examinations and chemotherapy-related toxicity in pancreatic cancer patients. A secondary objective...
7.
Cekani E, Epistolio S, Dazio G, Cefali M, Wannesson L, Frattini M, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077640
In non-small cell lung cancer (NSCLC) the most common alterations are identified in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, accounting for approximately 30% of cases in Caucasian...
8.
Deantonio L, Garo M, Paone G, Valli M, Cappio S, La Regina D, et al.
Front Oncol
. 2022 Apr;
12:861638.
PMID: 35371989
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42021274636.
9.
Cefali M, Epistolio S, Ramelli G, Mangan D, Molinari F, Martin V, et al.
J Clin Med
. 2022 Mar;
11(6).
PMID: 35329953
Background: Immune checkpoint inhibitors (ICIs) targeting PD-1 or PD-L1 improved the survival of non-small cell lung cancer (NSCLC) patients with PD-L1 expression ≥50% and without alterations in EGFR, ALK, ROS1,...
10.
Epistolio S, Cefali M, Spina P, Molinari F, Movilia A, Cergnul M, et al.
Oncotarget
. 2021 Jun;
12(11):1046-1056.
PMID: 34084279
Background: A disappearance of RAS mutations in the plasma of about 50% of mCRCs (metastatic colorectal cancers) treated with bevacizumab-based chemotherapy has been reported. Our aim was to evaluate the...